Recruitment for complementary/alternative medicine trials: Who participates after breast cancer

Annals of Behavioral Medicine

Volumn 20, Issue 3, 1998, Pages 190-198

  Richardson, Mary Ann ^a   Post White, Janice ^b   Singletary, S Eva ^b   Justice, Blair ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; COPING BEHAVIOR; FEMALE; HEALTH SURVEY; HUMAN; MARRIAGE; MEDICAL RESEARCH; PATIENT SELECTION; PSYCHOSOCIAL DISORDER; REIMBURSEMENT; RISK FACTOR; SOCIAL SUPPORT;

EID: 0032448316     PISSN: 08836612     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02884960     Document Type: Article

References (59)

1. Eisenberg D, Kessler RC, Foster C, et al: Unconventional medicine in the United States: Prevalence, costs, and patterns of use. New England Journal of Medicine. 1993, 328:246-252.
2. Cassileth BR, Lusk EF, Strouse TB, Bodenheimer BJ: Contemporary unorthodox treatments in cancer medicine: A study of patients, treatments, and practitioners. Annals of Internal Medicine. 1984, 101:105-112.
3. American Cancer Society: Unproven methods of cancer management-Macrobiotic diets for the treatment of cancer. CA: A Cancer Journal for Clinicians. 1989, 39(4):248-251.
4. Lerner IJ, Kennedy BJ: The prevalence of questionable methods of cancer treatments in the United States. Cancer. 1992, 42:181-191.
5. U.S. House Select Committee on Aging: Quackery: A Ten Billion Dollar Scandal. 98th Congress, 2nd Session: May 31, 1984. Washington, DC: U.S. Government Printing Office.
6. Herbert V: Unproven (questionable) dietary and nutritional methods in cancer prevention and treatment. Cancer. 1986, 58:1930-1941.
7. Ernst E: Complementary cancer treatments: Hope or hazard? Clinical Oncology. 1995, 7:259-263.
8. Gordon J: Alternative medicine and the family physician. American Family Physician. 1996, 54(7):2205-2212.
9. Richardson MA: Alternative cancer therapies: Facilitating information and evaluations. Third Annual International Congress on Alternative and Complementary Therapies. Washington, DC: September, 1997.
10. McGinnis LS: Alternative therapies, 1990. An overview. Cancer. 1991, 67:1788-1793.
11. Cassileth BR: Unorthodox cancer medicine. Cancer Investigation. 1986, 4:591-598.
12. Mock V, Hill MN, Dienemann JA, Grimm PM, Shivnan JC: Challenges to behavioral research in oncology. Cancer Practice. 1996, 4(5):267-273.
13. Hunningshake DB, Darby CA, Probstfield JL: Recruitment experience in clinical trials: Literature summary and annotated bibliography. Controlled Clinical Trials. 1987, 9(Suppl.):6S-30S.
14. Leventhal H, Nerenz DR, Leventhal EA, Love RR, Bendena LM: The behavioral dynamics of clinical trials. Preventive Medicine. 1991, 20:132-146.
15. Daly D: Alternative medicine courses taught at U.S. medical schools: An ongoing listing. Journal of Alternative and Complementary Medicine. 1996, 2:315-317.
16. Weil A: The body's healing systems: The future of medical education. Alternative and Complementary Therapies. 1995, September: 305-310.
17. Ernst E, Resch K, White AR: Complementary medicine: What physicians think of it - A meta-analysis. Archives of Internal Medicine. 1995, 155:2405-2408.
18. Goodwin J: A health insurance revolution. New Age Journal. 1997, April:95-99.
19. Weber DO: The mainstreaming of alternative medicine. Healthcare Forum Journal. 1966, Nov/Dec: 16-27.
20. Office of Alternative Medicine Clearing House-NIH: OAM highlights strategic plan for AMPAC. Complementary and Alternative Medicine at the NIH. 1997, 4(4):1.
21. Winn RJ: Obstacles to the accrual of patients to clinical trials in the community setting. Seminars in Oncology. 1994, 21(4):112-117.
22. Gotay CC: Accrual to cancer clinical trials: Directions from the research literature. Social Science and Medicine. 1991, 33(5):569-577.
23. Winn RJ, Miransky J, Kerner JF, et al (eds): An evaluation of physician determinants in the referral of patients for cancer clinical trials in the community setting. In Advances in Cancer Control: Epidemiology and Research. New York: Liss, 1984, 63-73.
24. Benson AB, Pregler JP, Bean JA, et al: Oncologists' reluctance to accrue patients onto clinical trials: An Illinois cancer center study. Journal of Clinical Oncology. 1991, 9:2607.
25. Mackillop WJ, Ward GK, O'Sullivan B: The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. British Journal of Cancer. 1986, 54:661-667.
26. Moore JJ, O'Sullivan B, Tannack IF: How expert physicians would wish to be treated if they had genitourinary cancer. Journal of Clinical Oncology. 1988, 6:1736-1745.
27. Taylor KM, Klener M: Informed consent: A physicians' perspective. Social Science and Medicine. 1987, 24:135-147.
28. Penman DT, Holland JC, Bahna GF, et al: Informed consent for investigational chemotherapy: Patients' and physicians' perceptions. Journal of Clinical Oncology. 1984, 2(7):849-855.
29. Boring CC, Quires TS, Tong T: Cancer statistic. CA: A Cancer Journal for Clinicians. 1991, 41:19-36.
30. Barofsky I, Sugarbaker PH: Determinants of patient nonparticipation in randomized clinical trial for the treatment of sarcomas. Cancer Clinical Trials. 1979, 2:237-246.
31. Hunter CP, Frelick RW, Feldman AR: Selection factors in clinical trials: Results from the community clinical oncology program physician's patient log. Cancer Treatment Reports. 1987, 71:559-565.
32. Kemp N, Skinner E, Toms J: Randomized clinical trials of cancer treatment - A public opinion survey. Clinical Oncology. 1984, 10:155-161.
33. Llewellyn-Thomas HA, McGreal MJTE, Fine S, Erlichman C: Patients willingness to enter clinical trials: Measuring the association with perceived benefit and preference for decision participation. Social Science and Medicine. 1991, 32:35-42.
34. Sutherland HJ, Llewellyn-Thomas HA, Lockwood GA, Trichler DL, Till JE: Cancer patients: Their desire for information and participation in treatment decisions. Journal of Royal Society of Medicine. 1989, 82:260-263.
35. Mettlin C, Cummings KM, Walsh D: Risk factor and behavioral correlates of willingness to participate in cancer prevention trials. Nutrition and Cancer. 1985, 7:189-198.
36. Yeomans-Kinney A, Vernon SW, Frankowski RF, et al: Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer. 1995, 76(1):45-56.
37. Daly M, Seay J, Balshem A, Lerman C, Engstrom P: Feasibility of a telephone survey to recruit health maintenance organization members into a tamoxifen chemoprevention trial. Cancer Epidemiology, Biomarkers and Prevention. 1992, 1:413-416.
38. Hudman KS, Yeomans AY: Issues of enrollment bias in cancer chemoprevention trials. Cancer Bulletin. 1995, 47:339-342.
39. Lerman C, Rimer BK, Daly M, et al: Recruiting high risk women into a breast cancer health promotion trial. Cancer Epidemiology, Biomarkers and Prevention. 1994, 3:271-276.
40. Deans G, Bennett-Emslie GB, Weir J, Smith DC, Kaye SB: Cancer support groups - Who joins and why? British Journal of Cancer. 1988, 58:670-674.
41. Bauman LJ, Gervey R, Siegel K: Factors associated with cancer patients' participation in support groups. Journal of Psychosocial Oncology. 1992, 10(3):1-20.
42. Bresberg BA, Levenson JL: A survey of cancer support groups provided by the National Cancer Institute (NCI) clinical and comprehensive centers. Psycho-Oncology. 1993, 2:215-217.
43. Loescher LJ, Graham VE, Aickin M, Mcyskens FL, Surwit EA: Development of a contingency recruitment plan for a phase III chemoprevention trial of cervical dysplasia. Progress in Clinical and Biological Research. 1990, 339:1551-1563.
44. Fisher B: On clinical trial participation. Journal of Clinical Oncology. 1991, 9:1927-1930.
45. Begg CB, Engstromm PF: Eligibility and extrapolation in cancer clinical trials. Journal of Clinical Oncology. 1987, 5:962-968.
46. Spiegel D, Bloom JR: Group therapy and hypnosis reduces metastatic breast carcinoma pain. Psychosomatic Medicine. 1983, 45:333-339.
47. Fawzy FI, Fawzy NW, Hyun CS, et al: Effects of an early structured psychiatric intervention. Archives of General Psychiatry. 1993, 50:681-689.
48. Douglas S, Briones J, Chronister C: The incidence of reporting consent rates in nursing research articles. Image: The Journal of Nursing Scholarship. 1993, 26(1):35-40.
49. Cassileth BR, Lusk EJ, Miller DS, Hurwitz S: Attitudes toward clinical trials among patients and the public. Journal of the American Medical Association. 1982, 246(8):968-970.
50. Pocock SJ: Size of cancer clinical trials and stopping rules. British Journal of Cancer. 1978, 38:757-766.
51. Jack WJL, Chetty U, Rodger A: Recruitment to a prospective breast conservation trial: Why are so few patients randomized? British Medical Journal. 1991, 301:82-85.
52. Moye LA, Richardson MA, Post-White J, Justice B: Research methodology in psychoneuroimmunology: Rationale and design of the IMAGES-P Clinical Trial. Alternative Therapies in Health and Medicine. 1995, 1(2):34-39.
53. Hermanek P, Sobin LH (eds): TNM Classification of Malignant Tumors. Berlin, Germany: Springer Verlag, 1987.
54. Vinokur AD, Threatt BA, Caplan RD, Zimmerman BL: Physical and psychosocial functioning and adjustment to breast cancer: Long-term follow-up of a screening population. Cancer. 1989, 63:394-405.
55. Bal DG: Cancer in African-Americans. CA: A Cancer Journal for Clinicians. 1992, 42(1):5-17.
56. Miller HH, Bauman LJ, Friedman DR, DeCosse JJ: Psychosocial adjustment of familial polyposis patients and participation in a chemoprevention trial. International Journal of Psychiatry in Medicine. 1986, 16(3):211-230.
57. Levy SM, Haynes LT, Herberman RB, et al: Mastectomy versus breast conservation surgery: Mental health effects at long-term follow-up. Health Psychology. 1992, 11(6):349-354.
58. Morrow GR, Hickok JT, Burish TG: Behavioral aspects of clinical trials: An integrated framework from behavioral theory. Cancer. 1994, 74(Suppl.):2676-2682.
59. Borhani NO, Tonascia J, Schlundt DG, Prineas RJ, Jefferys JL: Recruitment in the hypertension prevention trial. Controlled Clinical Trials. 1989, 10(Suppl.):30-39.